What is SouthernBiotech?
Founded in 1982, SouthernBiotech specializes in supplying premium antibodies essential for research endeavors, spanning diagnostics, drug development, and discovery studies. Their comprehensive product portfolio includes primary and secondary antibodies, immunoreagents, and bespoke services meticulously designed to cater to the specific requirements of the scientific community. The company's commitment to advancing research is evident in its in-house production and rigorous validation protocols, ensuring the consistent quality and timely delivery of its offerings. SouthernBiotech's operational model emphasizes customer success through flexible, customizable solutions and responsive technical support.
How much funding has SouthernBiotech raised?
SouthernBiotech has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in SouthernBiotech
PPP
Public-Private Partnership
What's next for SouthernBiotech?
The recent large-scale, late-stage funding infusion positions SouthernBiotech for accelerated expansion and innovation. This strategic capital is expected to fuel advancements in their product development pipeline, potentially broadening their reach into new research modalities or enhancing their custom service capabilities. Given the company's long history and established reputation, this investment likely signals a strategic move to solidify market leadership and capitalize on emerging opportunities within the dynamic fields of biotechnology and pharmaceutical research. Future developments may include strategic partnerships or acquisitions to further enhance their market penetration and technological offerings.
See full SouthernBiotech company page
